Establishment Labs Reports 44.7% Revenue Growth to $59.9 Million in Latest Quarter

Establishment Labs Holdings Inc. reported significant financial performance improvements in its latest quarterly filing, with revenues reaching $59.9 million for the three months ended March 31, 2026, compared to $41.4 million in the same period of the previous year, marking a 44.7% increase. The company's gross profit also rose to $42.3 million, resulting in a gross margin of 70.7%, up from 67.2% in the prior year. Despite these gains, the company recorded a net loss of $13.4 million, a reduction from the $20.7 million loss reported in the first quarter of 2025.

The increase in revenue was primarily driven by a $13.5 million rise in sales within the United States, following the FDA approval for Motiva Implants in September 2024. International sales also contributed, with a $5 million increase mainly in the Asia-Pacific region and Latin America. The cost of revenue increased by 28.7% to $17.5 million, consistent with the revenue growth, while operating expenses rose to $48.8 million, reflecting higher sales, general, and administrative costs.

In terms of strategic developments, the company underwent a leadership transition, appointing Cassandra Harris as the new Chief Financial Officer, effective March 9, 2026. Additionally, on April 30, 2026, Establishment Labs entered into an Amended and Restated Credit Agreement, securing up to $300 million in new term loans, with the first tranche of $265 million already advanced. This funding is expected to enhance the company's liquidity and support its operational needs.

Operationally, Establishment Labs reported a cash balance of $68.1 million as of March 31, 2026, down from $75.6 million at the end of 2025. The company has maintained a focus on expanding its market presence, particularly in the U.S., where it has seen a substantial increase in customer engagement. The total number of shares outstanding increased slightly to 29.8 million, reflecting ongoing equity compensation activities.

Looking ahead, Establishment Labs anticipates continued revenue growth driven by the adoption of its Motiva Implants and ongoing product development efforts. However, the company remains cautious about potential market risks, including competition and regulatory challenges, which could impact its financial performance. The management believes that the available cash and anticipated cash flow from operations will be sufficient to meet liquidity requirements for at least the next 12 months.